S

Stoke Therapeutics
D

STOK

11.430
USD
0.17
(1.51%)
Market Closed
Volume
6,170
EPS
-2
Div Yield
-
P/E
-5
Market Cap
605,412,547
News

Title: Stoke Therapeutics

Sector: Healthcare
Industry: Biotechnology
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.